Cystatin C Medication-Driven Changes: What Drugs Raise or Lower Your Results

Cystatin C is a small protein (about 13 kDa) made by essentially every nucleated cell in the body at a fairly steady rate, then filtered by the glomerulus and broken down in the proximal tubule. It is not a drug or a supplement; it is a lab test, usually reported alongside or instead of creatinine to estimate glomerular filtration rate (GFR). Because its production is not tied to muscle mass the way creatinine's is, cystatin C is often the better choice for estimating kidney function in people with unusual body composition, whether from age, illness, or medications.

The useful clinical question is not simply "is cystatin C better than creatinine," but which medications and physiologic states change cystatin C independent of true kidney function, and how a clinician should sequence retesting before concluding a patient has new or worsening chronic kidney disease (CKD).

Cystatin C is filtered by the kidney and its production also responds to non-renal signals: glucocorticoid exposure, thyroid status, and possibly large, rapid changes in lean body mass. That means a cystatin C level can rise or fall without any true change in glomerular filtration rate, and it also means a discordance between creatinine-eGFR and cystatin C-eGFR is expected, not alarming, in patients on these therapies. Under the 2022 KDIGO CKD guideline, a diagnosis of chronic kidney disease still requires confirmation with a second measurement of eGFR and albuminuria at least 90 days apart, not a single abnormal value drawn during an active medication effect.

Why cystatin C is used instead of, or alongside, creatinine

Creatinine production tracks muscle mass, which varies by age, sex, and body composition, so creatinine-based eGFR can overestimate true kidney function in people with low muscle mass (older adults, cirrhosis, amputation, chronic illness) and underestimate it in people with high muscle mass. Cystatin C production is driven by housekeeping gene expression across essentially all cells rather than by muscle bulk, which is why professional nephrology guidance recommends it as a confirmatory or preferred marker in specific situations rather than as a universal replacement.

The 2021 CKD-EPI cystatin C and combined creatinine-cystatin C equations removed race as a variable and were developed with input from a large multi-cohort validation effort; this is well established and widely adopted (Inker et al., New England Journal of Medicine, 2021). If your lab reports "eGFR-cystatin C," confirm with them which equation version they use, since older 2012-era equations are still in circulation at some laboratories.

When cystatin C adds real value over creatinine alone

Situations where creatinine-eGFR is least reliable, and where cystatin C is most useful as a cross-check, include:

• Body mass index well below 18.5 or above roughly 35 kg/m²
• Older age with reduced muscle mass or frailty
• Cirrhosis or significant protein-calorie malnutrition
• Testosterone or other anabolic therapy, which raises creatinine through increased muscle mass
• Substantial recent weight loss, including from GLP-1 receptor agonist therapy

Normal range versus a "healthier" range: keep these separate

The standard laboratory reference interval (commonly cited as roughly 0.62 to 1.15 mg/L, though this varies by assay and lab) describes the middle of a population that includes many people with early or subclinical kidney or cardiometabolic disease. It is a statement of what is common, not a statement of what is optimal.

Several large observational cohorts, including the ARIC study and the Health ABC study, have reported that higher cystatin C values within or near the "normal" range are associated with greater long-term cardiovascular and all-cause mortality risk, even in people whose creatinine-eGFR looks normal. These are observational associations, not causal proof that lowering cystatin C itself improves outcomes, and the exact thresholds and hazard ratios attributed to these cohorts should be checked against the primary papers before being used to counsel an individual patient. Verification note: this draft could not confirm a specific hazard ratio or percentage from these cohorts against a primary source, so none is stated here.

A practical, non-diagnostic working target

Medication and physiology confounder checklist for cystatin C

Before treating an abnormal cystatin C as evidence of new kidney disease, work through this sequence. It reflects site practice built from the general pharmacology described in this article, not a validated clinical decision rule, and it does not replace individualized clinical judgment.

The unifying rule: when creatinine-eGFR and cystatin C-eGFR disagree by a clinically meaningful margin, ask what is happening to muscle mass, glucocorticoid exposure, and thyroid status before ordering additional kidney imaging or making dosing changes to renally cleared drugs.

Medications reported to raise cystatin C independent of kidney function

Corticosteroids

Among medications, glucocorticoids are most clearly shown to elevate cystatin C independent of actual kidney function, acting by increasing cystatin C production in cells rather than by changing GFR. Pharmacokinetic studies demonstrate that high-dose intravenous corticosteroids can raise serum cystatin C measurably within 24 hours while true kidney function (as shown by methods like inulin clearance) remains stable, and this elevation typically resolves within several days after stopping the medication. While the kidney medicine community widely accepts this phenomenon, earlier versions of this article cited specific effect sizes and sample numbers that could not be confirmed in primary sources for this revision, so quantitative details are not included. When a patient receives significant systemic corticosteroid therapy around the time of testing, this context should be noted with the cystatin C result, and any new CKD classification should not be based solely on that measurement.

Inhaled corticosteroids at standard respiratory doses are not expected to meaningfully affect cystatin C.

Calcineurin inhibitors: ciclosporin and tacrolimus

These drugs can raise cystatin C by two overlapping mechanisms: genuine nephrotoxicity that lowers true GFR, and an additional, GFR-independent increase in cystatin C production. Transplant nephrology literature has described cystatin C-based equations overestimating the degree of GFR reduction caused by calcineurin inhibitors compared with directly measured clearance methods. Clinicians managing transplant recipients on these drugs typically rely on measured GFR rather than equation-based eGFR for dosing decisions; this is standard transplant practice, and the precise magnitude of overestimation should be confirmed against the primary transplant nephrology literature before being quoted to a patient.

High-dose methotrexate

Oncology-range methotrexate doses (well above the 15 to 25 mg weekly doses used in rheumatology) have been associated in case reports with transient cystatin C elevation. At standard rheumatologic dosing, no clinically significant effect on cystatin C is expected, and cystatin C remains a reasonable monitoring tool in that population.

Thyroid status and thyroid hormone therapy

Hypothyroidism is associated with both reduced GFR and, independently, higher cystatin C levels. Correcting hypothyroidism toward a normal TSH has been reported to lower cystatin C over a period of weeks, without a comparable change in creatinine. This makes cystatin C a plausible, though not formally validated, way to gauge whether a patient on thyroid hormone replacement is adequately treated when symptoms and TSH do not clearly agree. The exact magnitude of change reported in small studies should be verified before it is used as a specific counseling number.

Medications and physiologic states associated with lower cystatin C

SGLT2 inhibitors

SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, others) cause a well-known early drop in creatinine-based eGFR in the first weeks of treatment, driven by reduced pressure inside the glomerulus rather than kidney injury. Cystatin C-based eGFR typically shows a smaller, more gradual change during this period, which is why some clinicians prefer to track cystatin C during SGLT2 initiation rather than reacting to the early creatinine dip. The DAPA-CKD trial is a well-established, large randomized trial that demonstrated a meaningful reduction in kidney disease progression with dapagliflozin in patients with CKD; the specific magnitude of its cystatin C-based secondary endpoints should be checked directly against the published trial report before being cited with an exact number.

GLP-1 receptor agonists

Semaglutide and similar GLP-1 receptor agonists are not known to directly change cystatin C synthesis. In patients with obesity-related glomerular hyperfiltration, meaningful weight loss can reduce that hyperfiltration, which in turn can lower cystatin C. The FLOW trial is a real, large randomized outcomes trial of semaglutide in patients with type 2 diabetes and CKD that reported a reduction in kidney disease progression; again, any specific cystatin C-based eGFR slope figure attributed to this trial needs confirmation against the primary publication rather than being repeated as an established number here.

Testosterone replacement therapy

Testosterone therapy increases skeletal muscle mass, which boosts creatinine production and can artificially worsen creatinine-based eGFR estimates despite unchanged actual kidney function. Because cystatin C is independent of muscle mass, it provides a more reliable assessment of kidney function in men receiving testosterone. The TRAVERSE trial evaluated cardiovascular outcomes in hypogonadal men with existing cardiovascular disease or risk factors who received testosterone therapy. An earlier draft of this article cited a specific cystatin C-based eGFR analysis from TRAVERSE; this particular finding could not be confirmed in the primary literature during this revision and should not be considered established without further verification. From a physiologic standpoint, however, when a man on testosterone shows rising creatinine alongside stable cystatin C, the increase in muscle mass is a more likely explanation than kidney function decline, and observing this pattern justifies measuring cystatin C to clarify whether actual renal function has changed.

Renally cleared drugs where the choice of GFR marker can change dosing

Getting the GFR estimate right matters most for drugs with a narrow therapeutic window that are cleared by the kidney.

Anticoagulants (apixaban, rivaroxaban): Current FDA-approved dosing criteria for apixaban use serum creatinine, not cystatin C, as one of the standard dose-reduction criteria. Some cardiology and nephrology groups have discussed using cystatin C-based eGFR to refine dosing decisions in borderline cases, particularly in patients with low muscle mass where creatinine may overestimate true kidney function, but the FDA label itself has not incorporated cystatin C. This is an area of evolving practice, not an approved labeling change, as of this writing (dated January 2025; confirm current FDA labeling before relying on this for a dosing decision).

Metformin: The FDA contraindication threshold is an eGFR below 30 mL/min/1.73m², with added caution in the 30 to 45 range. In patients where creatinine likely overestimates true GFR (for example, frail older adults with low muscle mass), checking cystatin C may show adequate kidney function and support continuing a drug with broader metabolic and cardiovascular benefit, rather than withholding it based on a creatinine-eGFR that understates true filtration.

Aminoglycosides and vancomycin: These require accurate GFR estimates for dosing intervals. Cystatin C-based equations are generally considered to perform better than creatinine-only equations in critically ill patients with abnormal creatinine generation, such as those with rhabdomyolysis or acute liver failure, though individual dosing should still follow institutional pharmacy protocols and, where available, drug-level monitoring.

Timing a cystatin C test around medications

• If the goal is a baseline unaffected by a corticosteroid course, wait at least a few days after stopping systemic steroids before drawing cystatin C.
• Around a new SGLT2 inhibitor, check a baseline before starting and consider a repeat at roughly 8 to 12 weeks to see the true trend rather than reacting to the early hemodynamic dip.
• On thyroid hormone therapy, wait until TSH has been stable at target for several weeks before treating a cystatin C value as representative.
• In men on stable-dose testosterone therapy, allow muscle mass to plateau (commonly several months) before comparing cystatin C and creatinine trends.

No fasting is required for cystatin C testing.

Interpreting an eGFR-cystatin C report

1. Confirm the equation. Ask the lab to confirm use of the 2021 CKD-EPI cystatin C or combined equation rather than an older, race-based 2012-era formula.
2. Screen the medication list for the drug classes above, and note the timing of the most recent dose relative to the blood draw.
3. Compare with creatinine-eGFR. A meaningful discordance between the two usually points to one of: unusually high or low muscle mass, active corticosteroid use, uncontrolled hypothyroidism, or a genuine change in kidney function that both markers are tracking imperfectly.
4. Confirm before diagnosing CKD. Per the 2022 KDIGO CKD guideline, chronic kidney disease requires at least two abnormal measurements of eGFR (and, where relevant, albuminuria) separated by at least 90 days. A single abnormal cystatin C, especially one drawn during a medication effect, does not meet that bar.

What is established, what is plausible, and what is not established

Established: Cystatin C is produced independent of skeletal muscle mass, is filtered by the glomerulus, and the 2021 CKD-EPI cystatin C and combined equations are validated, race-free tools for eGFR estimation. Systemic corticosteroids and calcineurin inhibitors are recognized in the nephrology literature to affect cystatin C through mechanisms partly or wholly separate from true GFR. KDIGO's 2022 guideline requires two separated abnormal measurements before diagnosing CKD.

Plausible but not fully proven for individual dosing decisions: That cystatin C should replace creatinine for anticoagulant dose-adjustment in borderline renal function; that a specific numeric "optimal" cystatin C threshold below the standard reference range reduces an individual's cardiovascular or mortality risk if targeted directly, as opposed to simply correlating with better health; that GLP-1-associated weight loss reliably lowers cystatin C by resolving hyperfiltration in every patient with obesity.

Not established from the material available for this article: Precise percentage changes in cystatin C attributed to specific corticosteroid doses, calcineurin inhibitor regimens, or a post-hoc TRAVERSE analysis of testosterone therapy. These specific figures appeared in an earlier draft without a confirmable primary source and have been removed or flagged rather than restated as fact. Anyone updating this page for publication should verify each numeric claim against the named trial's primary publication before it is reinstated.

A note on sources. This article draws on well-established, widely cited literature: the KDIGO 2022 CKD guideline, the CKD-EPI 2021 equation development and validation work (Inker et al., New England Journal of Medicine, 2021), and large randomized trials including DAPA-CKD, FLOW, and TRAVERSE for background on the underlying drug classes. Several specific numeric effect sizes that appeared in an earlier version of this page (percentage changes in cystatin C from corticosteroids, calcineurin inhibitors, and a testosterone trial post-hoc analysis) could not be independently confirmed against a verified primary source during this revision and have been removed or clearly flagged as requiring verification rather than presented as fact. Anyone finalizing this page for publication should locate and cite the exact primary papers before restoring any specific percentage, hazard ratio, or sample size.